ClinicalTrials.gg
Active, not recruitingNCT05609370Updated Jul 23, 2026Results posted

A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

A Phase 1/2 interventional study of Alcestobart and Tislelizumab in Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, sponsored by BeiGene. Active, not recruiting at 64 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by BeiGene · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing tislelizumab in Colorectal Neoplasms — 15 open to participants now, 19 under way, 1 of them phase 3. tislelizumab · Colorectal Neoplasms.

Enrollment
3rd of 27
113 · median 33
Started
2023
with 7 others
Phase 1/2
4 of 27
2 open now
Primary completion
2025-05
later than 5 of 18 live
Registered
11th of 27
by date
Lead sponsor
2 of 27
BeiGene

Among the 27 studies testing tislelizumab in Colorectal Neoplasms, this one is the 3rd largest by enrollment, is one of 8 that started in 2023, is one of 4 in phase 1/2, reaches primary completion later than 5 of the 18 other live ones, and was the 11th registered.

Colorectal Neoplasms

6,545 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

15 of the 27 studies testing tislelizumab in Colorectal Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing tislelizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This is a Phase 1b/2 study to investigate the efficacy and safety of alcestobart (LBL-007) plus tislelizumab when administered in combination with bevacizumab plus fluoropyrimidine, and alcestobart in combination with bevacizumab plus fluoropyrimidine versus bevacizumab plus fluoropyrimidine to participants with colorectal cancer.

03

Conditions studied

  • Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Keywords

  • Colorectal Cancer
  • Microsatellite Stable
  • Mismatch Repair Proficient
  • Maintenance Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must have as defined per ((Response Evaluation Criteria in Solid Tumors) version 1.1
  • Has a confirmed colorectal adenocarcinoma with or unresectable disease (Stage IV as defined by American Joint Committee on Cancer [AJCC] 8th edition)
  • No prior systemic therapy for colorectal cancer (CRC) in the metastatic setting except for the induction treatment of therapy. Note: Local regional treatment performed during induction systemic treatment is allowed
  • Participants who have completed the first-line induction treatment, with an overall response of stable disease or better. The duration of induction treatment should be completed within approximately 6 months. The first dose of study treatment needs to occur within 2 weeks (for 2-week regimen) or 3 weeks (for 3-week regimen) to 6 weeks after Day 1 of the last cycle of induction therapy

Exclusion criteria

Exclusion Criteria:

  • Participants whose disease has become resectable at the investigator's discretion during or after induction treatment are not eligible
  • Progressive disease occurred less than 6 months from completion of any prior therapy (ie, chemotherapy with or without radiotherapy) or adjuvant therapy (ie, chemotherapy with or without radiotherapy), whichever occurred later
  • Participants who have been treated with anti-epidermal growth factor receptor (EGFR) antibody in the induction treatment
  • Any prior therapy targeting T-cell stimulation or checkpoint pathways
  • Participants with B-raf proto-oncogene, serine/threonine kinase (BRAF)V600E mutations
  • Have locally or centrally confirmed microsatellite instability-high (MSI-H) by polymerase chain reaction (PCR) method or dMMR by immunohistochemistry (IHC) method

Note: Other protocol defined criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    Phase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine

    Participants received alcestobart low dose, tislelizumab, bevacizumab and capecitabine until disease progression, unacceptable toxicity, or withdrawal of consent.

    Drug: Alcestobart · Drug: Tislelizumab · Drug: Bevacizumab or Bevacizumab biosimilar · Drug: Fluoropyrimidine (FP)

  • Experimental
    Phase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine

    Participants received alcestobart medium dose, tislelizumab, bevacizumab and fluoropyrimidine until disease progression, unacceptable toxicity, or withdrawal of consent. The alcestobart, tislelizumab, and bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen).

    Drug: Alcestobart · Drug: Tislelizumab · Drug: Bevacizumab or Bevacizumab biosimilar · Drug: Fluoropyrimidine (FP)

  • Experimental
    Phase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine

    Participants received alcestobart high dose, tislelizumab, bevacizumab and fluoropyrimidine until disease progression, unacceptable toxicity, or withdrawal of consent. The alcestobart, tislelizumab, and bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen).

    Drug: Alcestobart · Drug: Tislelizumab · Drug: Bevacizumab or Bevacizumab biosimilar · Drug: Fluoropyrimidine (FP)

  • Experimental
    Phase 2: Arm A:PD-L1-positive: Alcestobart High Dose +Tislelizumab + Bevacizumab +Fluoropyrimidine

    PD-L1 (programmed cell death protein ligand-1)-positive participants received alcestobart high dose, tislelizumab, bevacizumab and fluoropyrimidine until disease progression, unacceptable toxicity, or withdrawal of consent. The alcestobart, tislelizumab, and bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen).

    Drug: Alcestobart · Drug: Tislelizumab · Drug: Bevacizumab or Bevacizumab biosimilar · Drug: Fluoropyrimidine (FP)

  • Experimental
    Phase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + Fluoropyrimidine

    PD-L1-positive participants received alcestobart high dose, bevacizumab and fluoropyrimidine until disease progression, unacceptable toxicity, or withdrawal of consent. The alcestobart and bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen).

    Drug: Alcestobart · Drug: Bevacizumab or Bevacizumab biosimilar · Drug: Fluoropyrimidine (FP)

  • Active comparator
    Phase 2: Arm C: PD-L1-positive: Bevacizumab + Fluoropyrimidine

    PD-L1-positive participants received bevacizumab and fluoropyrimidine in combination with leucovorin or levoleucovorin (LV) until disease progression, unacceptable toxicity, or withdrawal of consent. The bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen).

    Drug: Bevacizumab or Bevacizumab biosimilar · Drug: Fluoropyrimidine (FP)

  • Experimental
    Phase 2: Arm D: PD-L1-negative: Alcestobart High Dose+ Tislelizumab+ Bevacizumab+ Fluoropyrimidine

    PD-L1-negative participants received alcestobart high dose, tislelizumab, bevacizumab and fluoropyrimidine until disease progression, unacceptable toxicity, or withdrawal of consent. The alcestobart, tislelizumab, and bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen).

    Drug: Alcestobart · Drug: Tislelizumab · Drug: Bevacizumab or Bevacizumab biosimilar · Drug: Fluoropyrimidine (FP)

  • Active comparator
    Phase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine

    PD-L1-negative participants received bevacizumab and fluoropyrimidine in combination with LV until disease progression, unacceptable toxicity, or withdrawal of consent. The bevacizumab dosing frequency was based on the selected fluoropyrimidine regimen (5-FU/LV 2-week regimen or capecitabine 3-week regimen).

    Drug: Bevacizumab or Bevacizumab biosimilar · Drug: Fluoropyrimidine (FP)

Interventions

  • Administered intravenously (IV) at one of the following doses * Low dose: 150 mg once every 3 weeks * Medium dose: 300 mg once every 3 weeks or 200 mg once every 2 weeks * High dose: 600 mg once every 3 weeks or 400 mg once every 2 weeks

    Also known as: LBL-007

  • Administered intravenously at a dose of either 200 mg once every 3 weeks or 300 mg once every 4 weeks.

    Also known as: BGB-A317

  • DrugBevacizumab or Bevacizumab biosimilar

    Administered intravenously at a dose of either 7.5 mg/kg once every 3 weeks or 5 mg/kg once every 2 weeks.

  • Fluoropyrimidine treatment included one of the following: \- Capecitabine 850 mg/m\^2 administered orally twice daily for the first 2 weeks of each 3-week cycle, OR \- 5-fluorouracil (5-FU) 1600 to 2400 mg/m\^2 continuous infusion over 46 to 48 hours in combination with leucovorin or levoleucovorin (LV) IV administered per local guidelines and/or prescribing information once every 2 weeks.

06

What researchers measure

Primary outcomes

  1. Phase 1b: Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatments, whether considered related to study treatments or not. A serious AE (SAE) was any untoward medical occurrence that, at any dose- * resulted in death, * was life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.

    Time frame: From first dose of study drug up to 30 days after last dose; maximum time on treatment was 16.2 months.

  2. Phase 2: Progression Free Survival (PFS) as Assessed by The Investigator in PD-L1 Positive Arms A and C

    PFS, as assessed by the investigator per RECIST v1.1 is defined as the time from the date of randomization to the date of first documentation of disease progression or death, whichever occured first.

    Time frame: From randomization until disease progression, death, study discontinuation, or data cutoff, whichever occurred first (maximum follow-up time: Arm A, 11.0 months, Arm C, 8.0 months)

Secondary outcomes

  1. Phase 2: Objective Response Rate (ORR) as Assessed by The Investigator in PD-L1 Positive Arms A and C

    ORR is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) from the time of randomization. CR and PR were confirmed per RECIST v1.1. * CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm. * PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From randomization until disease progression, death, study discontinuation, or data cutoff, whichever occurred first (maximum follow-up time: Arm A, 11.0 months, Arm C, 8.0 months)

  2. Phase 2: Duration of Response (DOR) as Assessed by The Investigator in PD-L1 Positive Arms A and C

    DOR is defined as the time from the first determination of an objective confirmed response after randomization until the first documentation of disease progression or death, whichever comes first.

    Time frame: From first documented response until disease progression or death (maximum follow-up time for DOR was 4.2 months)

  3. Phase 2: Progression Free Survival (PFS) as Assessed by The Investigator in PD-L1 Negative Arms D and E

    PFS, as assessed by the investigator per RECIST v1.1 is defined as the time from the date of randomization to the date of first documentation of disease progression or death, whichever occurs first.

    Time frame: From randomization until disease progression, death, study discontinuation, or data cutoff, whichever occurred first (maximum follow-up time: Arm D, 10.6 months, Arm E, 10.5 months)

  4. Phase 2: Objective Response Rate (ORR) as Assessed by The Investigator in PD-L1 Negative Arms D and E

    ORR is defined as the proportion of participants with a confirmed complete response (CR) or partial response (PR) from the time of randomization. CR and PR were confirmed per RECIST v1.1. * CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm. * PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From randomization until disease progression, death, study discontinuation, or data cutoff, whichever occurred first (maximum follow-up time: Arm D, 10.6 months, Arm E, 10.5 months))

  5. Phase 2: Duration of Response (DOR) as Assessed by The Investigator in PD-L1 Negative Arms D and E

    DOR, defined as the time from the first confirmed objective response after randomization until the first documentation of disease progression or death, whichever comes first.

    Time frame: From first documented response until disease progression or death (maximum follow-up time for DOR was 2.8 months)

  6. Phase 2: Number of Participants With Treatment-emergent AEs and SAEs

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatments, whether considered related to study treatments or not. A serious AE (SAE) was any untoward medical occurrence that, at any dose- * resulted in death, * was life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.

    Time frame: From first dose of study drug up to 30 days after last dose; maximum time on treatment in Phase 2 was 10.9 months

07

Results

Posted Jun 30, 2026

Participant flow

The study began in January 2023 and was conducted in 3 countries. The study consisted of Phase 1b and Phase 2. Phase 1b was completed as planned. On 20 December 2024, the sponsor decided to close enrollment in Phase 2 before achieving the planned sample size. Participants who continued to benefit from the study drugs were permitted to continue treatment in an Extended treatment Period which is currently ongoing.

Participant flow — Overall Study
MilestonePhase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +FluoropyrimidinePhase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + FluoropyrimidinePhase 2: Arm C: PD-L1-positive: Bevacizumab + FluoropyrimidinePhase 2:Arm D:PD-L1-negative: Alcestobart High Dose+ Tislelizumab + Bevacizumab + FluoropyrimidinePhase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine
Started6136189162223
Treated6136189142222
Completed01000000
Not completed6126189162223
Withdrew: Withdrawal by subject10110314
Withdrew: Study terminated by sponsor32265585
Withdrew: Death13100022
Withdrew: Physician decision00111000
Withdrew: Other01001010
Withdrew: Continuing in extended treatment period16110281012

Outcome measures

PrimaryPhase 1b: Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)

An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatments, whether considered related to study treatments or not. A serious AE (SAE) was any untoward medical occurrence that, at any dose- * resulted in death, * was life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.

Time frame:
From first dose of study drug up to 30 days after last dose; maximum time on treatment was 16.2 months.
Reported as:
Count of participants · Participants
Phase 1b: Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)
ParticipantsPhase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine
Treatment emergent adverse event6136
Serious adverse event383
PrimaryPhase 2: Progression Free Survival (PFS) as Assessed by The Investigator in PD-L1 Positive Arms A and C

PFS, as assessed by the investigator per RECIST v1.1 is defined as the time from the date of randomization to the date of first documentation of disease progression or death, whichever occured first.

Time frame:
From randomization until disease progression, death, study discontinuation, or data cutoff, whichever occurred first (maximum follow-up time: Arm A, 11.0 months, Arm C, 8.0 months)
Reported as:
Median · months
Phase 2: Progression Free Survival (PFS) as Assessed by The Investigator in PD-L1 Positive Arms A and C
monthsPhase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +FluoropyrimidinePhase 2: Arm C: PD-L1-positive: Bevacizumab + Fluoropyrimidine
Phase 2: Progression Free Survival (PFS) as Assessed by The Investigator in PD-L1 Positive Arms A and CNA (3.5 to NA)4.4 (2.1 to NA)
Statistical analysis
  • Phase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +Fluoropyrimidine vs Phase 2: Arm C: PD-L1-positive: Bevacizumab + Fluoropyrimidine · Regression, Cox · Hazard ratio (hr): 0.37 · 95% CI 0.10 to 1.33
SecondaryPhase 2: Objective Response Rate (ORR) as Assessed by The Investigator in PD-L1 Positive Arms A and C

ORR is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) from the time of randomization. CR and PR were confirmed per RECIST v1.1. * CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm. * PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From randomization until disease progression, death, study discontinuation, or data cutoff, whichever occurred first (maximum follow-up time: Arm A, 11.0 months, Arm C, 8.0 months)
Reported as:
Number · Percentage of participants
Phase 2: Objective Response Rate (ORR) as Assessed by The Investigator in PD-L1 Positive Arms A and C
Percentage of participantsPhase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +FluoropyrimidinePhase 2: Arm C: PD-L1-positive: Bevacizumab + Fluoropyrimidine
Phase 2: Objective Response Rate (ORR) as Assessed by The Investigator in PD-L1 Positive Arms A and C5.6 (0.1 to 27.3)0.0 (0.0 to 20.6)
SecondaryPhase 2: Duration of Response (DOR) as Assessed by The Investigator in PD-L1 Positive Arms A and C

DOR is defined as the time from the first determination of an objective confirmed response after randomization until the first documentation of disease progression or death, whichever comes first.

Time frame:
From first documented response until disease progression or death (maximum follow-up time for DOR was 4.2 months)
Reported as:
Median · months
Phase 2: Duration of Response (DOR) as Assessed by The Investigator in PD-L1 Positive Arms A and C
monthsPhase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +FluoropyrimidinePhase 2: Arm C: PD-L1-positive: Bevacizumab + Fluoropyrimidine
Phase 2: Duration of Response (DOR) as Assessed by The Investigator in PD-L1 Positive Arms A and CNA (NA to NA)—
SecondaryPhase 2: Progression Free Survival (PFS) as Assessed by The Investigator in PD-L1 Negative Arms D and E

PFS, as assessed by the investigator per RECIST v1.1 is defined as the time from the date of randomization to the date of first documentation of disease progression or death, whichever occurs first.

Time frame:
From randomization until disease progression, death, study discontinuation, or data cutoff, whichever occurred first (maximum follow-up time: Arm D, 10.6 months, Arm E, 10.5 months)
Reported as:
Median · months
Phase 2: Progression Free Survival (PFS) as Assessed by The Investigator in PD-L1 Negative Arms D and E
monthsPhase 2: Arm D: PD-L1-negative: Alcestobart High Dose+ Tislelizumab+ Bevacizumab+ FluoropyrimidinePhase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine
Phase 2: Progression Free Survival (PFS) as Assessed by The Investigator in PD-L1 Negative Arms D and E6.5 (3.9 to NA)10.4 (4.1 to NA)
Statistical analysis
  • Phase 2: Arm D: PD-L1-negative: Alcestobart High Dose+ Tislelizumab+ Bevacizumab+ Fluoropyrimidine vs Phase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine · Regression, Cox · Hazard ratio (hr): 1.22 · 95% CI 0.46 to 3.29
SecondaryPhase 2: Objective Response Rate (ORR) as Assessed by The Investigator in PD-L1 Negative Arms D and E

ORR is defined as the proportion of participants with a confirmed complete response (CR) or partial response (PR) from the time of randomization. CR and PR were confirmed per RECIST v1.1. * CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm. * PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From randomization until disease progression, death, study discontinuation, or data cutoff, whichever occurred first (maximum follow-up time: Arm D, 10.6 months, Arm E, 10.5 months))
Reported as:
Number · Percentage of participants
Phase 2: Objective Response Rate (ORR) as Assessed by The Investigator in PD-L1 Negative Arms D and E
Percentage of participantsPhase 2: Arm D: PD-L1-negative: Alcestobart High Dose+ Tislelizumab+ Bevacizumab+ FluoropyrimidinePhase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine
Phase 2: Objective Response Rate (ORR) as Assessed by The Investigator in PD-L1 Negative Arms D and E0.0 (0.0 to 15.4)4.3 (0.1 to 21.9)
SecondaryPhase 2: Duration of Response (DOR) as Assessed by The Investigator in PD-L1 Negative Arms D and E

DOR, defined as the time from the first confirmed objective response after randomization until the first documentation of disease progression or death, whichever comes first.

Time frame:
From first documented response until disease progression or death (maximum follow-up time for DOR was 2.8 months)
Reported as:
Median · months
Phase 2: Duration of Response (DOR) as Assessed by The Investigator in PD-L1 Negative Arms D and E
monthsPhase 2: Arm D: PD-L1-negative: Alcestobart High Dose+ Tislelizumab+ Bevacizumab+ FluoropyrimidinePhase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine
Phase 2: Duration of Response (DOR) as Assessed by The Investigator in PD-L1 Negative Arms D and E—NA (NA to NA)
SecondaryPhase 2: Number of Participants With Treatment-emergent AEs and SAEs

An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatments, whether considered related to study treatments or not. A serious AE (SAE) was any untoward medical occurrence that, at any dose- * resulted in death, * was life threatening, * required hospitalization or prolongation of existing hospitalization, * resulted in disability/incapacity, * was a congenital anomaly/birth defect.

Time frame:
From first dose of study drug up to 30 days after last dose; maximum time on treatment in Phase 2 was 10.9 months
Reported as:
Count of participants · Participants
Phase 2: Number of Participants With Treatment-emergent AEs and SAEs
ParticipantsPhase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab + Bevacizumab +FluoropyrimidinePhase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + FluoropyrimidinePhase 2: Arm C: PD-L1-positive: Bevacizumab + FluoropyrimidinePhase 2: Arm D: PD-L1-negative: Alcestobart High Dose+ Tislelizumab+ Bevacizumab+ FluoropyrimidinePhase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine
Treatment Emergent adverse event179132222
Serious adverse event31374

Adverse events

Collected over Mortality was collected up to the end of the main part of the study, maximum time on study was 22.9 months. Adverse events were assessed from first dose of study drug to 30 days after last dose, maximum time on treatment was 16.2 months.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine1/6 (16.7%)3/6 (50%)6/6 (100%)
Phase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine3/13 (23.1%)8/13 (61.5%)13/13 (100%)
Phase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine1/6 (16.7%)3/6 (50%)6/6 (100%)
Phase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +Fluoropyrimidine0/18 (0%)3/18 (16.7%)17/18 (94.4%)
Phase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + Fluoropyrimidine0/9 (0%)1/9 (11.1%)9/9 (100%)
Phase 2: Arm C: PD-L1-positive: Bevacizumab + Fluoropyrimidine0/16 (0%)3/14 (21.4%)12/14 (85.7%)
Phase 2:Arm D:PD-L1-negative: Alcestobart High Dose + Tislelizumab+ Bevacizumab+ Fluoropyrimidine2/22 (9.1%)7/22 (31.8%)21/22 (95.5%)
Phase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine2/23 (8.7%)4/22 (18.2%)22/22 (100%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventPhase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +FluoropyrimidinePhase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + FluoropyrimidinePhase 2: Arm C: PD-L1-positive: Bevacizumab + FluoropyrimidinePhase 2:Arm D:PD-L1-negative: Alcestobart High Dose + Tislelizumab+ Bevacizumab+ FluoropyrimidinePhase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine
Intestinal obstructionGastrointestinal disorders1/60/130/60/181/90/140/221/22
Jaundice cholestaticHepatobiliary disorders1/60/130/60/180/90/140/220/22
PneumoniaInfections and infestations0/60/131/60/180/90/140/220/22
Diabetic ketoacidosisMetabolism and nutrition disorders0/60/131/60/180/90/140/220/22
KetoacidosisMetabolism and nutrition disorders0/60/131/60/180/90/140/220/22
Cerebral infarctionNervous system disorders1/60/130/60/180/90/140/220/22
CoughRespiratory, thoracic and mediastinal disorders0/60/131/60/180/90/140/220/22
Immune-mediated lung diseaseRespiratory, thoracic and mediastinal disorders1/60/130/60/180/90/140/220/22
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/60/130/60/180/90/140/220/22
ColitisGastrointestinal disorders0/62/130/60/180/90/140/220/22
Most frequent other events
Showing 10 of 296
Most frequent other events
EventPhase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +FluoropyrimidinePhase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + FluoropyrimidinePhase 2: Arm C: PD-L1-positive: Bevacizumab + FluoropyrimidinePhase 2:Arm D:PD-L1-negative: Alcestobart High Dose + Tislelizumab+ Bevacizumab+ FluoropyrimidinePhase 2: Arm E: PD-L1-negative: Bevacizumab + Fluoropyrimidine
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders3/61/135/63/183/91/145/225/22
HyperthyroidismEndocrine disorders0/60/134/62/180/90/142/220/22
Alanine aminotransferase increasedInvestigations4/62/133/63/180/91/141/221/22
AnaemiaBlood and lymphatic system disorders3/62/131/61/181/92/142/225/22
HypothyroidismEndocrine disorders1/65/133/65/180/90/144/220/22
StomatitisGastrointestinal disorders1/63/133/60/181/91/142/223/22
Aspartate aminotransferase increasedInvestigations2/62/133/63/180/91/142/223/22
White blood cell count decreasedInvestigations3/61/133/61/181/91/142/221/22
Decreased appetiteMetabolism and nutrition disorders3/62/131/64/180/91/144/222/22
DiarrhoeaGastrointestinal disorders0/65/131/65/180/91/142/223/22

Baseline characteristics

113 participants were enrolled in the study, 110 participants received study drugs, 2 participants in Arm C and 1 participant in Arm E were randomized but not treated due to withdrawal by participant

Age, Continuous
Age, Continuous(years)Phase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +FluoropyrimidinePhase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + FluoropyrimidinePhase 2: Arm C: PD-L1-positive: Bevacizumab + FluoropyrimidinePhase 2:Arm D:PD-L1-negative: Alcestobart High Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 2: Arm E: PD-L1-negative: Bevacizumab + FluoropyrimidineTotal
Mean58.5 ± 7.6657.8 ± 13.2753.7 ± 11.6254.6 ± 11.1663.0 ± 9.7556.3 ± 14.1861.1 ± 11.2458.1 ± 10.4258.0 ± 11.51
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +FluoropyrimidinePhase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + FluoropyrimidinePhase 2: Arm C: PD-L1-positive: Bevacizumab + FluoropyrimidinePhase 2:Arm D:PD-L1-negative: Alcestobart High Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 2: Arm E: PD-L1-negative: Bevacizumab + FluoropyrimidineTotal
Female48285871153
Male2541048151260
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +FluoropyrimidinePhase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + FluoropyrimidinePhase 2: Arm C: PD-L1-positive: Bevacizumab + FluoropyrimidinePhase 2:Arm D:PD-L1-negative: Alcestobart High Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 2: Arm E: PD-L1-negative: Bevacizumab + FluoropyrimidineTotal
Not Hispanic or Latino6106169142222105
Hispanic or Latino020001014
Not reported010201004
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +FluoropyrimidinePhase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + FluoropyrimidinePhase 2: Arm C: PD-L1-positive: Bevacizumab + FluoropyrimidinePhase 2:Arm D:PD-L1-negative: Alcestobart High Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 2: Arm E: PD-L1-negative: Bevacizumab + FluoropyrimidineTotal
Asian5551267141569
White1613375632
Other010000102
Not reported010101014
Unknown000001001
Multiple000200215
Region of Enrollment
Region of Enrollment(Participants)Phase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +FluoropyrimidinePhase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + FluoropyrimidinePhase 2: Arm C: PD-L1-positive: Bevacizumab + FluoropyrimidinePhase 2:Arm D:PD-L1-negative: Alcestobart High Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 2: Arm E: PD-L1-negative: Bevacizumab + FluoropyrimidineTotal
United States1615255429
China4431357141666
Australia1320243318
Liver Metastases: Yes/No
Liver Metastases: Yes/No(Participants)Phase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 1b: Alcestobart High Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 2: Arm A: PD-L1-positive: Alcestobart High Dose +Tislelizumab +Bevacizumab +FluoropyrimidinePhase 2: Arm B: PD-L1-positive: Alcestobart High Dose + Bevacizumab + FluoropyrimidinePhase 2: Arm C: PD-L1-positive: Bevacizumab + FluoropyrimidinePhase 2:Arm D:PD-L1-negative: Alcestobart High Dose + Tislelizumab + Bevacizumab + FluoropyrimidinePhase 2: Arm E: PD-L1-negative: Bevacizumab + FluoropyrimidineTotal
Yes512413613141885
No1125338528
08

Study locations

64 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beigene.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in May 2025, 27 months.

Results were first posted in Jun 2026, 1 year 1 month after primary completion.

Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 82. This study's 27 months is below that.

Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2022
First posted
Nov 8, 2022
StartActual
Jan 29, 2023
Primary completionActual
May 23, 2025
CompletionEst.
Dec 31, 2026
Results first posted
Jun 30, 2026
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05609370
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Nov 8, 2022
Start date
Jan 29, 2023
Primary completion
May 23, 2025
Completion
Dec 31, 2026 (estimated)
Results posted
Jun 30, 2026
Last update
Jul 23, 2026

Study contacts

Study Director
study director · BeiGene

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alcestobart · Tislelizumab

Start the discussion